Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | HTT | P42858 | 2/20 | 0.54 |
| ▸ | GAA | P10253 | 2/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
| ▸ | ERN1 | O75460 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | G6PD | P11413 | 1/20 | 0.44 |
| ▸ | GSK3B | P49841 | 1/20 | 0.43 |
| ▸ | ADK | P55263 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.43 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8685474 | 0.84 | HSD17B10 (0.50) | KDM4EHSD17B10GAAPTPN22ALDH1A1 | |
| SCHEMBL998061 | 0.83 | ELANE (0.42) | KDM4EHSD17B10MAPTHTTGAA | |
| SCHEMBL9488962 | 0.82 | HTT (0.54) | KDM4EHSD17B10MAPTHTTGAA | |
| SCHEMBL453345 | 0.82 | KDM4E (0.58) | KDM4EHSD17B10MAPTHTTGAA | |
| SCHEMBL10040401 | 0.82 | PTPN22 (0.47) | KDM4EHSD17B10MAPTGAAPTPN22 | |
| SCHEMBL29356413 | 0.82 | KDM4E (0.58) | KDM4EHSD17B10MAPTHTTGAA | |
| SCHEMBL9125063 | 0.81 | HSD17B10 (0.59) | KDM4EHSD17B10MAPTGAAPTPN22 | |
| SCHEMBL30060732 | 0.81 | NCEH1 (0.46) | KDM4EHSD17B10MAPTHTTGAA | |
| SCHEMBL6621295 | 0.81 | HPGD (0.46) | KDM4EHSD17B10MAPTHTTGAA | |
| SCHEMBL27409488 | 0.81 | HTT (0.45) | KDM4EHSD17B10MAPTHTTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1613326-B1 | (3-{3-'(2,4-BIS-TRIFLUORMETHYL-BENZYL)-(5-ETHYL-PYRIMIDIN-2-YL)-AMINO]-PROPOXY}-PHENYL)-ACETIC ACID AND RELATED COMPOUNDS AS MODULATORS OF PPARS AND METHODS OF TREATING METABOLIC DISORDERS | KALYPSYS INC (US) | 2006-09-13 | — | — | EP | disclosed |
| EP-1613326-A1 | (3-{3-´(2,4-BIS-TRIFLUORMETHYL-BENZYL)-(5-ETHYL-PYRIMIDIN-2-YL)-AMINO!-PROPOXY}-PHENYL)-ACETIC ACID AND RELATED COMPOUNDS AS MODULATORS OF PPARS AND METHODS OF TREATING METABOLIC DISORDERS | Kalypsys, Inc. (US) | 2006-01-11 | — | — | EP | disclosed |
| US-20050070532-A1 | Aryl compounds as modulators of PPARS and methods of treating metabolic disorders | KALYPSYS, INC. | 2005-03-31 | — | — | US | disclosed |
| WO-2004093879-A1 | (3-{3-‘(2,4-BIS-TRIFLUORMETHYL-BENZYL)-(5-ETHYL-PYRIMIDIN-2-YL)-AMINO!-PROPOXY}-PHENYL)-ACETIC ACID AND RELATED COMPOUNDS AS MODULATORS OF PPARS AND METHODS OF TREATING METABOLIC DISORDERS | KALYPSYS, INC. (US) | 2004-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070532-A1 | Aryl compounds as modulators of PPARS and methods of treating metabolic disorders | PPARG, PPARA, PPARD | KDM4E 2778/4885HSD17B10 131/4885MAPT 3770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.